Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)
A phase 2 trial of Zelenectide pevedotin, Pembrolizumab, Carboplatin, Cisplatin, Gemcitabine and Gemcitabine + cisplatin in bladder & urothelial cancer, run by BicycleTx Limited, active and no longer recruiting.
Overview
Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2) is a phase 2 interventional study registered as NCT06225596 by BicycleTx Limited, with 375 participants enrolled, started 2024-01-24 and due to reach its primary completion in 2028-03. Interventions recorded: Zelenectide pevedotin, Pembrolizumab, Gemcitabine + cisplatin Or carboplatin and Avelumab.
Similar pages
not linked directly; found by shared links- TrialPhase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy
Shares Gemcitabine, Cisplatin, Carboplatin, Bladder & urothelial cancer and the tag pipeline.
- Trial9MW2821 in Combination With Toripalimab vs Standard Chemotherapy in Locally Advanced or Metastatic Urothelial Cancer
Shares Gemcitabine, Cisplatin, Carboplatin, Bladder & urothelial cancer and the tag pipeline.
- TrialDisitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2
Shares Gemcitabine, Cisplatin, Carboplatin, Bladder & urothelial cancer and the tag pipeline.
- TrialStudy of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer (PEARL)
Shares Gemcitabine + cisplatin, Gemcitabine, Cisplatin, Carboplatin and the tag pipeline.
- TrialStudy of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma
Shares Gemcitabine, Cisplatin, Carboplatin, Bladder & urothelial cancer and the tag pipeline.
- TrialPhase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC)
Shares Gemcitabine + cisplatin, Gemcitabine, Cisplatin, Carboplatin and the tag pipeline.
- TrialStudy of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE)
Shares Gemcitabine + cisplatin, Gemcitabine, Cisplatin, Carboplatin and the tag pipeline.
- TrialDurvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs)
Shares Gemcitabine + cisplatin, Gemcitabine, Cisplatin, Carboplatin and the tag pipeline.